KNSA
Kiniksa Pharmaceuticals LtdKey Statistics
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on addressing significant unmet medical needs through the development of advanced therapies. Its lead candidate, KPL-404, is a monoclonal antibody designed to modulate immune response, offering promising potential for the treatment of autoimmune disorders. With a strong pipeline supported by ongoing clinical trials and strategic partnerships, Kiniksa is well-positioned for growth in the competitive pharmaceutical market. The company’s commitment to scientific innovation and its goal of redefining treatment paradigms make it an attractive opportunity for institutional investors looking to invest in transformative biopharmaceutical solutions.
Fundamentals
| Revenue (TTM) | $754.04M |
| Gross Profit (TTM) | $412.11M |
| EBITDA | $94.89M |
| Operating Margin | 13.70% |
| Return on Equity | 13.70% |
| Return on Assets | 8.18% |
| Revenue/Share (TTM) | $10.03 |
| Book Value | $7.44 |
| Price-to-Book | 6.74 |
| Price-to-Sales (TTM) | 5.43 |
| EV/Revenue | 4.809 |
| EV/EBITDA | 38.21 |
| Quarterly Earnings Growth (YoY) | 145.50% |
| Quarterly Revenue Growth (YoY) | 55.50% |
| Shares Outstanding | $46.30M |
| Float | $40.29M |
| % Insiders | 3.57% |
| % Institutions | 101.81% |
Historical Volatility
Volatility is currently contracting